Kintara Therapeutics Inc represents a strong commitment to improving patients' lives through innovative therapies and solutions. The company values scientific excellence, integrity, and collaboration to drive significant advancements in the field of biopharmaceuticals. Kintara Therapeutics Inc is dedicated to developing and commercializing novel therapies for the treatment of cancer and other debilitating diseases. With a focus on precision medicine, the company aims to bring transformative therapies to patients in need. Through their cutting-edge research and strategic partnerships, Kintara Therapeutics Inc strives to make a meaningful impact in the healthcare industry and enhance patient outcomes.

Kintara Therapeutics Inc is primarily present in the United States.

Some significant milestones that Kintara Therapeutics Inc has achieved include advancing their lead product candidate, VAL-083, through various stages of development, including successful completion of Phase 1 and Phase 2 clinical trials. The company has also received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for VAL-083 in the treatment of glioblastoma multiforme, an aggressive brain cancer. Kintara Therapeutics Inc has also expanded its pipeline by acquiring two additional novel cancer therapies, further amplifying their potential growth opportunities. These achievements highlight the company's progress and dedication towards advancing innovative and effective treatments for cancer patients.

Kintara Therapeutics Inc, a renowned biopharmaceutical company, boasts an impressive history and background. Founded in 2006, the company is committed to developing innovative therapies targeting unmet medical needs. Kintara focuses on advancing novel molecules to potentially treat various forms of cancer. Leveraging its experienced team, the company strives to provide patients with safe, effective, and transformative treatment options. Over the years, Kintara Therapeutics Inc has demonstrated remarkable dedication to research and development, fostering collaborations, and leveraging cutting-edge technologies. With its strong focus on improving patient outcomes and its impressive track record, Kintara Therapeutics Inc continues to solidify its position in the biopharmaceutical industry.

The main competitors of Kintara Therapeutics Inc in the market include other pharmaceutical companies working in the field of oncology research and development. Some notable competitors in this industry are Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, and Pfizer Inc. These companies also focus on developing innovative therapies to treat various types of cancers, just like Kintara Therapeutics Inc. As a pharmaceutical company specializing in cancer therapies, Kintara Therapeutics Inc faces competition from these established players in the market.

Kintara Therapeutics Inc is primarily active in the pharmaceutical industry.

The business model of Kintara Therapeutics Inc is focused on developing and commercializing innovative therapies for the treatment of cancer. They aim to address unmet medical needs and improve the lives of patients through their research and development efforts. By leveraging their expertise in novel drug candidates, clinical trials, and strategic partnerships, Kintara Therapeutics Inc aims to bring effective and targeted therapies to market. Their business model emphasizes collaboration, scientific rigor, and a patient-centric approach to drug development.

Pomer Kintara Therapeutics cena/zisk je -14,57.

Koeficient Kintara Therapeutics P/S je 0.

AlleAktien kvalitatívne skóre pre Kintara Therapeutics je 2/10.

Aktuálne nie je možné vypočítať obrat pre Kintara Therapeutics.

Zisk Kintara Therapeutics je -8,50 mil. USD.

Kintara Therapeutics Inc is a US biotechnology company specializing in the research and development of novel drugs for the treatment of cancer and neurodegenerative diseases. It was founded in 2013 and is headquartered in San Diego, California. The company's business model is based on three pillars: the discovery and development of new compounds, knowledge transfer through partnerships with other companies and academies, and the clinical development and marketing of drugs. Kintara Therapeutics Inc is working on discovering and developing novel therapies for a variety of indications. Its current focus areas include T-cell lymphomas and brain tumors such as glioblastomas, which are particularly difficult to treat. The company utilizes a variety of technologies, including in-house platforms and external partnerships, to identify potential drug candidates. Kintara Therapeutics Inc has a range of products in its pipeline, currently undergoing various stages of clinical development. This includes the drug VAL-083, which is being tested in Phase 3 trials for the treatment of glioblastomas. Additionally, the company is developing CAR-T cell therapies for the treatment of T-cell lymphomas. In terms of knowledge transfer partnerships, Kintara Therapeutics Inc collaborates closely with other companies and academic institutions to expand the potential of its research programs and accelerate the development of new medical treatment options. Another important element of Kintara Therapeutics Inc's business model is the clinical development and marketing of drugs. The company has an experienced team of clinical development and marketing experts who are able to bring innovative products to market. Kintara Therapeutics Inc also works with licensing partners to distribute its products internationally. In addition to its main business activities, Kintara Therapeutics Inc is also involved in other sectors of biotechnology. The company offers innovative technologies and services in the field of drug research, including drug manufacturing, formulation and development, and target molecule screening. Overall, Kintara Therapeutics Inc's business model consists of a diverse portfolio of technologies, research focuses, and partnerships aimed at developing and bringing to market novel and effective drugs for the treatment of serious diseases. Through its combined efforts in research and development, as well as clinical development and marketing activities, Kintara Therapeutics Inc has the potential to fundamentally change the way cancer and neurodegenerative diseases are treated.

Kintara Therapeutics vypláca dividendu vo výške 0 USD rozdelenú do výplat počas roka.

Dividenda pre Kintara Therapeutics sa aktuálne nedá vypočítať alebo spoločnosť nevypláca dividendu.

ISIN spoločnosti Kintara Therapeutics je US49720K1016.

WKN spoločnosti Kintara Therapeutics je A2QBU5.

Ticker spoločnosti Kintara Therapeutics je KTRA.

V posledných 12 mesiacoch spoločnosť Kintara Therapeutics vyplatila dividendu vo výške . To zodpovedá dividendovému výnosu približne . Pre nadchádzajúcich 12 mesiacov bude pravdepodobne spoločnosť Kintara Therapeutics vyplácať dividendu 0 USD.

Súčasný výnos z dividend spoločnosti Kintara Therapeutics je .

Kintara Therapeutics vypláca dividendu každý štvrťrok. Tá je vyplácaná v mesiacoch .

Kintara Therapeutics platil každý rok počas posledných 0 rokov dividendu.

Na nasledujúcich 12 mesiacov sa očakávajú dividendy vo výške 0 USD. To zodpovedá dividendovému výnosu 0 %.

Kintara Therapeutics je priradený sektoru 'Zdravie'.

Aby ste obdržali poslednú dividendu vo výške 0 USD od Kintara Therapeutics z dňa 20. 11. 2024, museli ste mať akciu v depozite pred ex-dňom 20. 11. 2024.

Posledná dividenda bola vyplatená 20. 11. 2024.

V roku 2023 boli od Kintara Therapeutics 0 USD vyplatené ako dividendy.

Dividendy spoločnosti Kintara Therapeutics sú vyplácané v USD.